WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 532621
Description: S-4048 is a very potent inhibitor of glucose-6-phosphate translocase (G6P T1). S-4048 acts as a gatekeeper to transport glucose 6-phosphate into the endoplasmic reticulum and therefore plays an important role in the regulation of blood glucose levels.
MedKoo Cat#: 532621
Chemical Formula: C32H30ClN3O7
Exact Mass: 603.1772
Molecular Weight: 604.06
Elemental Analysis: C, 63.63; H, 5.01; Cl, 5.87; N, 6.96; O, 18.54
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: S-4048; S 4048; S4048.
IUPAC/Chemical Name: (1S,3R,4R,5R)-1-[[(1R,2S)-2-(4-chlorophenyl)cyclopropyl]methoxy]-3,4-dihydroxy-5-[(Z)-3-imidazo[4,5-b]pyridin-1-yl-3-phenylprop-2-enoyl]oxycyclohexane-1-carboxylic acid
InChi Key: MYXPHMOLFCUDIL-MLFVSVOESA-N
InChi Code: InChI=1S/C32H30ClN3O7/c33-22-10-8-19(9-11-22)23-13-21(23)17-42-32(31(40)41)15-26(37)29(39)27(16-32)43-28(38)14-25(20-5-2-1-3-6-20)36-18-35-30-24(36)7-4-12-34-30/h1-12,14,18,21,23,26-27,29,37,39H,13,15-17H2,(H,40,41)/b25-14-/t21-,23+,26+,27+,29+,32-/m0/s1
SMILES Code: O=C([C@]1(OC[C@H]2[C@@H](C3=CC=C(Cl)C=C3)C2)C[C@@H](O)[C@@H](O)[C@H](OC(/C=C(N4C=NC5=NC=CC=C54)/C6=CC=CC=C6)=O)C1)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 604.06 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Grefhorst A, Schreurs M, Oosterveer MH, Cortés VA, Havinga R, Herling AW, Reijngoud DJ, Groen AK, Kuipers F. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1. Biochem J. 2010 Dec 1;432(2):249-54. doi: 10.1042/BJ20101225. PubMed PMID: 20854262.
2: Dubbelhuis PF, Van Sluijters DA, Blommaart EF, Gustafson LA, Van Woerkom GM, Herling AW, Burger HJ, Meijer AJ. Inhibition of autophagic proteolysis by inhibitors of phosphoinositide 3-kinase can interfere with the regulation of glycogen synthesis in isolated hepatocytes. Biochem J. 2002 Dec 15;368(Pt 3):827-33. PubMed PMID: 12371905; PubMed Central PMCID: PMC1223050.
3: Hosokawa M, Thorens B. Glucose release from GLUT2-null hepatocytes: characterization of a major and a minor pathway. Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E794-801. PubMed PMID: 11882499.
4: Herling AW, Schwab D, Burger HJ, Maas J, Hammerl R, Schmidt D, Strohschein S, Hemmerle H, Schubert G, Petry S, Kramer W. Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR(-)) by the glucose-6-phosphate translocase inhibitor S 3025. Biochim Biophys Acta. 2002 Jan 15;1569(1-3):105-10. PubMed PMID: 11853963.
5: Bandsma RH, Wiegman CH, Herling AW, Burger HJ, ter Harmsel A, Meijer AJ, Romijn JA, Reijngoud DJ, Kuipers F. Acute inhibition of glucose-6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes. 2001 Nov;50(11):2591-7. PubMed PMID: 11679439.
6: Gustafson LA, Neeft M, Reijngoud DJ, Kuipers F, Sauerwein HP, Romijn JA, Herling AW, Burger HJ, Meijer AJ. Fatty acid and amino acid modulation of glucose cycling in isolated rat hepatocytes. Biochem J. 2001 Sep 15;358(Pt 3):665-71. PubMed PMID: 11535127; PubMed Central PMCID: PMC1222100.
7: van Dijk TH, van der Sluijs FH, Wiegman CH, Baller JF, Gustafson LA, Burger HJ, Herling AW, Kuipers F, Meijer AJ, Reijngoud DJ. Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem. 2001 Jul 13;276(28):25727-35. Epub 2001 May 9. PubMed PMID: 11346646.
8: Burger HJ, Schubert G, Hemmerle H, Kramer W, Herling AW. Pharmacological interference with hepatic glucose production. Ann N Y Acad Sci. 1999 Nov 18;892:312-4. PubMed PMID: 10842672.
9: Herling AW, Burger H, Schubert G, Hemmerle H, Schaefer H, Kramer W. Alterations of carbohydrate and lipid intermediary metabolism during inhibition of glucose-6-phosphatase in rats. Eur J Pharmacol. 1999 Dec 10;386(1):75-82. PubMed PMID: 10611466.